Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (November 2013)
22 slides from Pyc Therapeutics's investor presentation, Nov 28, 2013
Slide 1: Harnessing Biodiversity for Peptide Therapeutics
BREAKTHROUGH PEPTIDE THERAPEUTICS For personal use only Harnessing Biodiversity for Peptide Therapeutics November 2013 1
Slide 2: Corporate Update
For personal use only Corporate Update
Slide 3: Corporate overview
Corporate overview § Opera0ons in Perth, Australia For personal use only § Phylomer® pep0de libraries derived from most structurally diverse genomes § ‘Discovery Alliance’ business model for rapid revenue growth – Already received >$5.8M in commiJed revenue in less than 4 years § Alliances with
Slide 4: Phylogica's partnerships span a wide range of areas
For personal use only Phylogica’s partnerships span a wide a range of areas Cell penetrating peptides Phylogica CNS Delivery Antimicrobials Vaccines 4
Slide 5: Recent highlights
Recent highlights § Expanded Janssen collabora0on on pep0de-‐drug conjugates to include For personal use only downstream biological valida0on of op0mal hits § Constructed 2nd genera0on libraries with increased diversity and sampling – increased library size to 400 billion pep0des § Filed New Pat
Slide 6: Re-capitalisation Strategy
Re-‐capa<lisa<on Strategy § Conversion of Conver0ble Note: For personal use only – Issued 140 Million fully Paid Shares § Announced Non-‐renounceable Rights Issue to Raise ~$6 Million – Fully underwriJen by Hockings Family with PaJersons as sub-‐ underwriters. – Issue 401 Million Shares at 1.5c
Slide 7: Top-10 shareholders
Top-‐10 shareholders Position Holder name Shares % of issued For personal use only 1 Hockings Family Office 116,1400,00 20% 2 Telethon Institute 20,605,501 3.35% 3 Paul Watt 17,197,326 2.91% 4 Citicorp Nominees Pty Ltd 14,719,673 2.53% 5 Andrew Swift 14,010,457 2.43% 6 John Jelbart 10,837,398 1.86%
Slide 8: Technology Introduction
For personal use only Technology Introduc<on
Slide 9: The Phylomer Drug Discovery Engine
The Phylomer Drug Discovery Engine ORFtrap For personal use only Autonomous Structure High Complexity Focussed Phylomer Libraries (>1011) (<1010) Macrocyclics Bacteria/ Archaea Func0onal Viruses Eukaryotes Domains Phage Protozoa High Throughput Screening Yeast Two Bacterial In vitro Hybrid Two Hybri
Slide 10: Uniquely integrated capabilities of Phylomer platform
For personal use only Uniquely integrated capabili<es of Phylomer plaQorm Phylogica’s unique discovery platform: § Discover and validate new therapeutic targets found inside cells Citron (Phenomica) (Citron Homology Domain) § Develop therapeutic peptide leads against such targets § Deliver therap
Slide 11: Majority of Therapeutic Targets are Intracellular
Majority of Therapeu<c Targets are Intracellular Cellular distribu0on of therapeu0c targets considered ‘druggable’ For personal use only (1,700-‐3,000 targets) • Small Molecules (10%) • An0bodies • Scaffolds • Pep0des • Small Molecules Undrugged (70%) Phylomers Phylomers Phylomers 12
Slide 12: Cell penetrating Phylomers (CPPs): gaining access to intracellular targets
Cell penetra<ng Phylomers (CPP’s): gaining access to intracellular targets For personal use only Phylomers can expand the druggable landscape by >10-‐fold!! 13
Slide 13: Discovery of Phylomer-derived Cell Penetrating Peptides
For personal use only Discovery of Phylomer-‐derived Cell Penetra<ng Pep<des
Slide 14: Nature's Modular Solution to Cell Penetration
Nature’s Modular Solu<on to Cell Penetra<on § The modular structure of Bacterial Toxins provides a template for improving For personal use only efficiency of cell penetra0on and cargo delivery § Modularity enable Phylomers to ‘Plug-‐n-‐Play’ with exis0ng therapies § Phylomer CPPs are customised f
Slide 15: Workflow for Janssen CPP Project
For personal use only Workflow for Janssen CPP Project Build Phylomer libraries fused to Janssen Cargo ✔ Screen for Phylomer CPPs using ‘Endosomal Escape ✔ Trap’ in mammalian cells Validate hits using microscopy and FACS ✔ Confirm functional delivery using therapeutic drugs Ongoing Split GFP Toxins P
Slide 16: Endosomal Escape Trap for efficient CPP Discovery
Endosomal Escape Trap for efficient CPP Discovery § Phylogica’s endosome escape trap for capture of CPPs which efficiently deliver For personal use only biologics cargoes into cell and out of endosome Cell Penetrating Peptides CPP CPP Endosomal Uptake (Traps 99.9% CPP) CPP CPP Endosomal escape Label La
Slide 17: Phylomer-mediated delivery of Janssen RBD cargo to mammalian cells
Phylomer-‐mediated delivery of Janssen RBD cargo to mammalian cells For personal use only § Increased binding/uptake of FITC-‐labeled PYC_RBD fusions at 2µM RBD TAT_RBD RBD_Phylomer 1 RBD_Phylomer 2 18
Slide 18: Phylogica Differentiation, Deals and Growth Strategy
For personal use only Phylogica Differen<a<on, Deals and Growth Strategy
Slide 19: Three overlapping strategic phases
For personal use only Three overlapping strategic phases 1. Partnering: generate near-‐term revenue from discovery alliances 2. Technological leadership: enhance plaaorm through value-‐adding upgrades 3. In-‐house drug development: build value by advancing internal products Revenue Generation Tec
Slide 20: Anticipated commercial milestones
An<cipated commercial milestones § Janssen: Exercise Op0on-‐to-‐Licence Agreement -‐ Q1 2014 For personal use only § Further Pharma deals around areas of exper0se such as: § Phenotypic screening for discovery and valida0on of new targets (Phenomica) § Efficient delivery of biologics by Phylomer
Slide 21: Acknowledgements
For personal use only Acknowledgements 22
Slide 22: Contact Details
Dr. Richard Hopkins Contact Details Dr. Paul Wab Chief Execu<ve Officer Chief Scien<fic Officer Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 For personal use only Fax: +61 8 9489 7700 Fax: +61 8 9489 7700 Mobile: +61 405 656 868 Mobile: +61 421 550 213 richardh@phylogica.com paulw@phylogica.com www.phylogic